DW71177
Product Specifications
UNSPSC Description
DW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia[1].
Target Antigen
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dw71177.html
Solubility
DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
CC1=NN=C2C(NCCCCNC(CC(C)C)=O)=NC3=CC(OC)=CC=C3N21
Molecular Weight
384.48
References & Citations
[1]Ali I, et al. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia. Eur J Med Chem. Published online December 16, 2023.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162088/DW71177-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162088/DW71177-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
2241311-72-6
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
R10632h EACH
Human TNFSF9 / Tumor necrosis factor ligand superfamily member 9 Recombinant Protein
Ask
View Details 
